Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy
FDA approves Scholar Rock Isembyld to treat spinal muscular atrophy in adults and pediatric patients two years and older.
Share
Why It Matters
Scholar Rock got FDA approval for a new spinal muscular atrophy medicine. This is a big win that shows the company can bring treatments to patients.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.